Table 4.
Group (N of pts) | Kyn | Trp | Kyn/Trp ratio | ||||
---|---|---|---|---|---|---|---|
Median ± SD | p value | Median ± SD | p value | Median ± SD | p value | ||
Luminal A (60 pts) | PCR (0) | NA | NA | NA | NA | NA | NA |
No pCR (13) | 1.710 ± 0.684 | NA | 36.70 ± 8.26 | NA | 0.042 ± 0.019 | NA | |
No relapse (53) | 1.775 ± 0.582 | 0.982 | 48.17 ± 13.02 | 0.442 | 0.038 ± 0.014 | 0.542 | |
Relapse (7) | 1.717 ± 0.501 | 44.67 ± 5.88 | 0.043 ± 0.009 | ||||
Luminal B (89 pts) | PCR (23) | 1.887 ± 0.327 | 0.001** | 44.77 ± 14.17 | 0.455 | 0.045 ± 0.011 | 0.029* |
No pCR (42) | 1.580 ± 0.463 | 43.47 ± 8.51 | 0.036 ± 0.011 | ||||
No relapse (79) | 1.807 ± 0.463 | 0.194 | 43.87 ± 10.53 | 0.447 | 0.038 ± 0.011 | 0.119 | |
Relapse (10) | 1.653 ± 0.389 | 46.93 ± 8.42 | 0.035 ± 0.006 | ||||
HER2-enriched (14 pts) | PCR (7) | 1.757 ± 0.790 | 0.234 | 39.73 ± 8.12 | 0.836 | 0.045 ± 0.018 | 0.295 |
No pCR (6) | 2.43 ± 0.956 | 42.42 ± 5.03 | 0.063 ± 0.028 | ||||
No relapse (10) | 1.828 ± 0.786 | 0.454 | 37.80 ± 6.67 | 0.076 | 0.047 ± 0.023 | 1 | |
Relapse (4) | 2.398 ± 1.135 | 46.13 ± 2.94 | 0.049 ± 0.026 | ||||
TNBC (39 pts) | PCR (13) | 1.707 ± 0.476 | 0.853 | 44.43 ± 7.98 | 0.511 | 0.037 ± 0.008 | 0.353 |
No pCR (22) | 1.777 ± 0.449 | 41.97 ± 10.87 | 0.042 ± 0.013 | ||||
No relapse (39) | 1.648 ± 0.450 | 0.707 | 44.78 ± 10.73 | 0.440 | 0.037 ± 0.012 | 0.761 | |
Relapse (7) | 1.813 ± 0.437 | 42.00 ± 4.65 | 0.042 ± 0.011 |
The corresponding p values for patients showing or not a pCR and for patients with or without relapse are reported in the table. A significance level of 0.05 is accepted (in italics)
Median value of Kyn, Trp and Kyn/Trp ratio in the different breast cancer subtypes according to the response to chemotherapy and relapse tested by the mean of the Mann–Whitney U test
Kyn kynurenine, Trp tryptophan, SD standard deviation, PCR pathological complete response, TNBC triple-negative breast cancer